38 completed, 7 terminated, 6 recruiting, 5 unknown. 60 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 60 | Completed 38, Terminated 7, Recruiting 6, Unknown 5, Not yet recruiting 2, Active not recruiting 1, Withdrawn 1 |
Follow Streptococcal Infections: new trials by email Literature Review of Streptococcal Infections trials Research Report on Streptococcal Infections
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Induction of Cross-protective Antibodies for Serogroup 33 by Pneumococcal Conjugate Vaccines Pneumococcal Vaccine - Vaccine, Pneumococcal Disease | Phase 4 | Recruiting | University of Alabama at Birmingham | 70 | 2026-07-01 | 2026-08-21 |
| Prophylaxis of Recurrent Erysipelas in Lower Limbs: compreSsion thErapy vs aNTibiotics and Compression Therapy. elastic stockings, Phenoxymethylpenicillin - Recurrent Erysipelas | Phase 4 | Not yet recruiting | University Hospital, Tours | 200 | 2026-04-01 | 2026-04-24 |
| Opportunistic Pneumococcal Immunisation Trial in MALnutrition Pneumococcal conjugate vaccine, Typhoid conjugate vaccine - Severe Acute Malnutrition in Childhood, Pneumococcal Disease | Phase 4 | Recruiting | Nick Fancourt | 214 | 2026-01-16 | 2026-10-08 |
| Beta-lactam Plus Levofloxacin to Enhance Therapy in Streptococcal Septicemia Beta-lactam monotherapy, Beta-lactam plus levofloxacin combination therapy - Bacteremia, Streptococcus Infection | Phase 4 | Recruiting | Mahidol University | 165 | 2026-01-08 | 2026-08-21 |
| Comparing Short to Standard Amoxicillin Course for Erysipelas Course of amoxicillin - Erysipelas | Phase 4 | Not yet recruiting | Assistance Publique - Hôpitaux de Paris | 656 | 2026-01-01 | 2025-08-12 |
| Immunogenicity and Safety PCV-20 of the Vaccine Administered During an Acute Febrile Illness in Adults Early intervention, Delayed intervention - Acute Febrile Illness, Pneumococcal Infections | Phase 4 | Recruiting | Centre Hospitalier Universitaire de Saint Etienne | 1052 | 2025-12-17 | 2026-03-30 |
| Carriage to Assess Protection of New Pneumococcal Vaccines - PCV15 PCV15, Streptococcus pneumoniae serotype 3, Placebo - Pneumococcal Disease, Pneumococcal Carriage | Phase 4 | Recruiting | University of Oxford | 106 | 2025-02-24 | 2025-04-15 |
| Concomitant Administration of the Novavax Vaccine and a 20-valent Pneumococcal Conjugate Vaccine in Adults Aged ≥60 Years NVX, PCV20, Placebo - COVID-19, Pneumococcal Infections | Phase 4 | Unknown | Medical University of Vienna | 256 | 2023-03-01 | 2023-03-15 |
| Lot-to-lot Consistency of 23-valent Pneumococcal Polysaccharide Vaccine Experimental 23-valent Pneumococcal - Pneumococcal Infections | Phase 4 | Completed | Sinovac Biotech Co., Ltd | 1800 | 2023-02-27 | 2023-09-18 |
| Evaluating the Effectiveness of a Pneumococcal Immunisation Campaign in a Camp for Internally Displaced People Pneumococcal conjugate vaccine - Pneumococcal Infections | Phase 4 | Active not recruiting | London School of Hygiene and Tropical Medicine | 2882 | 2022-11-27 | 2025-06-04 |
| Immunogenicity and Safety of 23-valent Pneumococcal Polysaccharide Vaccine Experimental 23-valent PPV, Control 23-valent PPV - Pneumococcal Infections | Phase 4 | Completed | Sinovac Biotech Co., Ltd | 1800 | 2022-10-25 | 2023-09-18 |
| A Study to Describe the Safety of a Vaccine (Called 13vPnC) in Healthy People 18 to 49 Years of Age in India 13-valent pneumococcal conjugate vaccine - Pneumococcal Disease | Phase 4 | Completed | Pfizer | 200 | 2022-10-06 | 2024-04-26 |
| Impact of Vitamin D in Rheumatoid Arthritis Vitamin D - Rheumatic Arthritis | Phase 4 | Completed | University of Pristina | 100 | 2022-03-01 | 2024-12-04 |
| A Clinical Trial of 23-valent Pneumococcal Polysaccharide Vaccine Investigational 23-valent PPV, Control 23-valent PPV - Pneumococcal Infections | Phase 4 | Completed | Sinovac Biotech Co., Ltd | 600 | 2021-09-10 | 2022-08-12 |
| Evaluation of Immunogenicity and Safety of Combined Immunization of COVAX (Produced in Wuhan) and PPV23 / IIV4 COVAX+PPV23;COVAX+IIV4, COVAX only (1st and 2nd dose), PPV23 for the 1st dose and IIV4 for the 2nd dose - Influenza, Human, Pneumonia, Pneumococcal | Phase 4 | Unknown | China National Biotec Group Company Limited | 1404 | 2021-05-06 | 2021-10-15 |
| Immunogenicity After Revaccination With 23-valent Pneumococcal Polysaccharide Vaccine: Healthy Elderly People Versus Diabetic Patients ProDiax-23 (PPSV23) - Pneumococcal Infections | Phase 4 | Unknown | Korea University Guro Hospital | 254 | 2021-05-01 | 2021-05-06 |
| Safety and Immunogenicity Following Meningococcal and Pneumococcal Immunization Among Adult People Living With HIV Neisseria meningitidis oligosaccharide conjugate vaccine and recombinant protein-based vaccine, 13 valent pneumococcal conjugate vaccine and 23 valent pneumococcal polysaccharide vaccine - Hiv, Meningococcal Infections | Phase 4 | Recruiting | Thomas Benfield | 55 | 2021-04-28 | 2021-05-06 |
| Evaluation of Immunogenicity and Safety of Combined Immunization of COVID-19 Vaccine (Produced in Beijing) and PPV23 / IIV4 COVAX+IIV4; COVAX+PPV23, COVAX only (1st and 2nd dose), IIV4 for the 1st dose and PPV23 for the 2nd dose - Influenza, Human, Pneumonia, Pneumococcal | Phase 4 | Completed | China National Biotec Group Company Limited | 1133 | 2021-03-10 | 2021-10-20 |
| Evaluation of Safety and Immunogenicity of Combined Immunization of PPV23 and IIV4 IIV4 and PPV23, IIV4, PPV23 - Influenza, Human, Pneumonia, Pneumococcal | Phase 4 | Completed | China National Biotec Group Company Limited | 1224 | 2020-09-11 | 2022-08-02 |
| Effectiveness of Intravenous Immunoglobulins (IVIG) in Toxic Shock Syndromes in Children PRIVIGEN (CSL Behring), Albumin - Staphylococcal Infection, Streptococcal Infection | Phase 4 | Withdrawn | Hospices Civils de Lyon | 2020-09-01 | 2021-05-03 |
Showing 20 of 60. Sign in to see all of them.
Pneumococcal Infections (36) · Pneumonia, Pneumococcal (11) · Influenza, Human (7) · Meningococcal Infections (5) · Erysipelas (4) · Impetigo (4) · Pneumonia (4) · Infections (3) · COVID-19 (2) · Cellulitis (2) · Diphtheria (2) · Rheumatic Fever (2) · Tetanus (2) · Acquired Immunodeficiency Syndrome (1)
Bacterial Infections (60) · Bacterial Infections and Mycoses (60) · Gram-Positive Bacterial Infections (60) · Infections (57) · Respiratory Tract Diseases (19) · Respiratory Tract Infections (18) · Lung Diseases (15) · Skin and Connective Tissue Diseases (12) · Pneumonia, Bacterial (11) · Pneumonia (10) · Virus Diseases (10) · Pneumococcal Infections (9) · RNA Virus Infections (9) · Skin Diseases (8)
Pneumococcal Vaccines (9) · 13-valent pneumococcal vaccine (6) · Heptavalent Pneumococcal Conjugate Vaccine (5) · 23-valent pneumococcal capsular polysaccharide vaccine (4) · PHiD-CV vaccine (3) · 10-valent pneumococcal conjugate vaccine (2) · Amoxicillin (2) · Influenza Vaccines (2) · 4CMenB vaccine (1) · 5-(tetradecyloxy)-2-furancarboxylic acid (1) · Acetaminophen (1) · Albumins (1) · Azithromycin (1) · Blood Specimen Collection (1) · Ceftriaxone (1)
Korea University Guro Hospital (4) · Pfizer (4) · China National Biotec Group Company Limited (3) · London School of Hygiene and Tropical Medicine (3) · Public Health England (3) · Sinovac Biotech Co., Ltd (3) · Wyeth is now a wholly owned subsidiary of Pfizer (3) · Assistance Publique - Hôpitaux de Paris (2) · GlaxoSmithKline (2) · Hospices Civils de Lyon (2) · University of Oxford (2) · Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) (1) · Agence de Médecine Préventive, France (1) · Centre Hospitalier Universitaire de Saint Etienne (1) · Dr. Frank Behrens (1)
China (9) · France (6) · United Kingdom (5) · United States (5) · Germany (3) · Netherlands (3) · Kenya (2) · South Korea (2) · Spain (2) · Argentina (1) · Belarus (1) · Burkina Faso (1) · Chile (1) · Costa Rica (1) · Denmark (1)
Elizabeth Coates, PhD (2) · Hee Jin Cheong, MD, PhD (2) · Adelaide A Hebert, M.D. (1) · Aleksander V Zhestkov, Professor (1) · Anatoly Uss, MD/PhD (1) · Andrei D Protasov, Professor (1) · Andrew Pollard, FRCPCH, PhD (1) · Anu Kantele, MD PhD (1) · Daniel M Musher (1) · Daniela M Ferreira, PhD (1)
PMID 14998500, PMID 16567982, PMID 19091990, PMID 19906895, PMID 20010312, PMID 20686433, PMID 21191076, PMID 24086113, PMID 24465570, PMID 24618837, PMID 24885384, PMID 25785969, PMID 25980426, PMID 26083474, PMID 27239929, PMID 27265450, PMID 27616471, PMID 28173960, PMID 28392142, PMID 28410813, PMID 28491950, PMID 29017280, PMID 29429807, PMID 29488477, PMID 29561248, PMID 29985978, PMID 30321312, PMID 30518331, PMID 32087733, PMID 32418789, PMID 35931636, PMID 37780234, PMID 39330966, PMID 39602629, PMID 39633426, PMID 39756693, PMID 40396505, PMID 40646666, PMID 41165164, PMID 41265006, PMID 41290307, PMID 42202846
2008 (1)